secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001641172-25-023968
Event type: earnings
Sentiment:  negative
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics Q2 revenue falls to $0.2M from $2.7M; net loss $7.7M
-------------------------------------------------------------------

- Revenue $0.2M vs $2.7M in Q2 2024; no grant revenue recognized in Q2 2025.
- Operating loss $8.1M vs $7.7M prior year; expenses down 19.1% to $8.2M.
- Net loss $7.7M ($0.23 per share) vs $7.6M ($0.25 per share) in Q2 2024.
- Cash & marketable securities $13.4M as of June 30, 2025; adjusted EBITDA loss $7.2M.
- On track to initiate clinical evaluations for Co-Dx PCR platform tests before year-end; enhanced COVID-19 test trial starting imminently.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000164117225023968/0001641172-25-023968-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000164117225023968/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023968

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer